JP2013522237A - トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 - Google Patents

トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 Download PDF

Info

Publication number
JP2013522237A
JP2013522237A JP2012557285A JP2012557285A JP2013522237A JP 2013522237 A JP2013522237 A JP 2013522237A JP 2012557285 A JP2012557285 A JP 2012557285A JP 2012557285 A JP2012557285 A JP 2012557285A JP 2013522237 A JP2013522237 A JP 2013522237A
Authority
JP
Japan
Prior art keywords
erbb3
antibody
breast cancer
inhibitor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012557285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522237A5 (enExample
Inventor
ビクター モヨ
ガブリエラ ガルシア
Original Assignee
メリマック ファーマシューティカルズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44513103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013522237(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by メリマック ファーマシューティカルズ インコーポレーティッド filed Critical メリマック ファーマシューティカルズ インコーポレーティッド
Publication of JP2013522237A publication Critical patent/JP2013522237A/ja
Publication of JP2013522237A5 publication Critical patent/JP2013522237A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2012557285A 2010-03-11 2011-03-11 トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 Pending JP2013522237A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31289510P 2010-03-11 2010-03-11
US61/312,895 2010-03-11
PCT/US2011/028129 WO2011112953A2 (en) 2010-03-11 2011-03-11 Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016045111A Division JP6185102B2 (ja) 2010-03-11 2016-03-09 トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用

Publications (2)

Publication Number Publication Date
JP2013522237A true JP2013522237A (ja) 2013-06-13
JP2013522237A5 JP2013522237A5 (enExample) 2014-04-24

Family

ID=44513103

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012557285A Pending JP2013522237A (ja) 2010-03-11 2011-03-11 トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用
JP2016045111A Expired - Fee Related JP6185102B2 (ja) 2010-03-11 2016-03-09 トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016045111A Expired - Fee Related JP6185102B2 (ja) 2010-03-11 2016-03-09 トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用

Country Status (20)

Country Link
US (4) US8895001B2 (enExample)
EP (2) EP2544680B1 (enExample)
JP (2) JP2013522237A (enExample)
KR (1) KR101798679B1 (enExample)
CN (1) CN102858335B (enExample)
AU (1) AU2011224186C1 (enExample)
BR (1) BR112012022802A2 (enExample)
CA (1) CA2792327C (enExample)
DK (1) DK2544680T3 (enExample)
EA (1) EA201201186A1 (enExample)
ES (1) ES2535503T3 (enExample)
IL (1) IL221693A (enExample)
MX (1) MX344355B (enExample)
NZ (1) NZ602084A (enExample)
PL (1) PL2544680T3 (enExample)
PT (1) PT2544680E (enExample)
SG (1) SG183532A1 (enExample)
UA (1) UA111149C2 (enExample)
WO (1) WO2011112953A2 (enExample)
ZA (1) ZA201206425B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2647388A1 (en) * 2007-02-16 2013-10-09 Merrimack Pharmaceuticals, Inc. Antibodies Against ERBB3 and Uses Thereof
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
JP5680671B2 (ja) 2009-12-22 2015-03-04 ロシュ グリクアート アーゲー 抗ｈｅｒ３抗体及びその使用
US8895001B2 (en) * 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
CU24094B1 (es) 2010-08-20 2015-04-29 Novartis Ag Anticuerpos para el receptor 3 del factor de crecimiento epidérmico(her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
MX2013010379A (es) * 2011-03-11 2014-03-27 Merrimack Pharmaceuticals Inc Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas.
SMT201900505T1 (it) 2011-03-31 2019-11-13 Adc Therapeutics Sa Anticorpi contro l'antigene 1 associato ai reni e loro frammenti leganti l'antigene
PH12013502663A1 (en) * 2011-06-30 2018-03-21 Merrimack Pharmaceuticals Inc Dosage administration of anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers
CA2849508C (en) 2011-09-30 2020-12-22 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
EP2764364B1 (en) * 2011-10-06 2021-08-18 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
US20140234308A1 (en) 2011-10-13 2014-08-21 The Regents Of The University Of California Treatment of breast cancer with companion diagnostic
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
CN104159924B (zh) * 2011-12-05 2018-03-16 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
PT2802351T (pt) * 2012-01-09 2019-06-27 Adc Therapeutics Sa Agentes para o tratamento de cancro da mama triplo negativo
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
EP2912062A1 (en) * 2012-10-24 2015-09-02 Yeda Research and Development Co. Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
EP2928488A1 (en) * 2012-12-07 2015-10-14 The General Hospital Corporation Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2015148971A2 (en) 2014-03-27 2015-10-01 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
MA45420A (fr) 2015-04-17 2019-05-01 Merrimack Pharmaceuticals Inc Traitements combinés avec seribantumab
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JP6823055B2 (ja) * 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
CN105375955B (zh) * 2015-10-26 2018-07-17 西安电子科技大学 一种信能同传中继网络中的协作传输方法
KR101746152B1 (ko) * 2015-12-07 2017-06-13 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
EP3387017A1 (en) 2015-12-11 2018-10-17 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
US20190091227A1 (en) 2016-03-15 2019-03-28 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
KR101923641B1 (ko) * 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
WO2020086412A1 (en) * 2018-10-21 2020-04-30 Slsg Limited Llc Combination immunotherapy for treatment of triple-negative breast cancer
AR117994A1 (es) * 2019-02-05 2021-09-08 Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet Métodos para tratar cáncer de mama triple negativo utilizando una proteína mutante de erbb-2 humana
CN112755173B (zh) * 2020-12-31 2022-01-07 深圳市科达顺生物技术有限公司 用于治疗三阴性乳腺癌的Ii-Key/HER2杂交多肽药物及其制备方法
CN117412766A (zh) * 2021-03-11 2024-01-16 艾利维申肿瘤学公司 抗erbb3(her3)单克隆抗体治疗与神经调节蛋白1(nrg1)基因融合相关肿瘤的剂量和给药

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019952A2 (en) * 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5344760A (en) 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6983227B1 (en) 1995-01-17 2006-01-03 Intertech Ventures, Ltd. Virtual models of complex systems
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
IL126303A (en) 1996-03-27 2002-05-23 Genentech Inc ErbB3 ANTIBODIES
ATE486937T1 (de) 1996-07-12 2010-11-15 Genentech Inc Chimärische heteromultimerische adhesine
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US20020002276A1 (en) 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
GB2336695A (en) 1998-04-20 1999-10-27 Teamware Group Oy Modelling a work process
CA2332331A1 (en) 1998-05-15 1999-11-25 Francisco Robert Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
HU231064B1 (hu) 1999-08-27 2020-03-30 Genentech, Inc. Anti-ErbB2 antitestek adagolási sémái és alkalmazásuk rákos betegségek kezelésére
US7390632B2 (en) 1999-09-30 2008-06-24 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP1285092A4 (en) 2000-04-14 2003-07-16 Metabolon Inc METHOD FOR DISCOVERY OF MEDICINES, DISEASE TREATMENT AND DIAGNOSIS USE THE METABOLOMICS
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US6871171B1 (en) 2000-10-19 2005-03-22 Optimata Ltd. System and methods for optimized drug delivery and progression of diseased and normal cells
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
PT2163256E (pt) * 2001-05-11 2015-11-20 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
US7612042B2 (en) 2001-05-31 2009-11-03 Tumor Biology Investment Group, Inc. Methods for inhibiting heregulin and treating cancer
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
AU2002326531A1 (en) 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
US20040248196A1 (en) 2001-08-03 2004-12-09 Adams Timothy Edward Methods of screening based on the egf receptor crystal structure
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
KR20050038578A (ko) 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
US7415359B2 (en) 2001-11-02 2008-08-19 Gene Network Sciences, Inc. Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
CA2480099C (en) 2002-03-26 2019-01-08 Zensun (Shanghai) Sci-Tech. Ltd. Erbb3 based methods and compositions for treating neoplasms
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040132097A1 (en) 2002-06-19 2004-07-08 Bacus Sarah S. Method for predicting response to epidermal growth factor receptor-directed therapy
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
ES2246191T1 (es) 2002-12-11 2006-02-16 Ventana Medical Systems, Inc. Metodo para predecir la respuesta a la terapia dirigida a her2.
BRPI0408950A (pt) 2003-04-01 2006-03-28 Monogram Biosciences Inc método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica
CA2534898A1 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
EP1664716A4 (en) 2003-08-15 2008-08-13 Smithkline Beecham Corp CANCER BIOMARKERS
US8554486B2 (en) 2004-02-20 2013-10-08 The Mathworks, Inc. Method, computer program product, and apparatus for selective memory restoration of a simulation
PT1733056E (pt) 2004-03-31 2013-08-29 Gen Hospital Corp Método para determinar a responsividade do cancro a tratamentos visando o receptor do factor de crescimento epidérmico
BRPI0510716A (pt) 2004-05-05 2007-11-20 Merrimack Pharmaceuticals Inc uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
AU2005249492B2 (en) 2004-05-27 2011-09-22 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
US7794960B2 (en) 2004-06-04 2010-09-14 Glaxosmithkline Llc Predictive biomarkers in cancer therapy
US7329737B2 (en) 2004-08-03 2008-02-12 Dyax Corp. Antibodies that bind hK-1
BRPI0513639A (pt) 2004-08-06 2008-05-13 Genentech Inc métodos de previsão da sensibilidade, métodos de indução da apoptose e métodos de tratamento de disfunção em mamìferos e de cáncer
AU2005272848A1 (en) 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
WO2006044378A2 (en) 2004-10-12 2006-04-27 University Of Iowa Research Foundation Rapid computational identification of targets
US20080254497A1 (en) 2004-10-15 2008-10-16 Monogram Biosciences, Inc. Response Predictors for Erbb Pathway-Specific Drugs
ZA200704796B (en) 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
KR20070114765A (ko) 2005-02-23 2007-12-04 메리맥 파마슈티컬즈, 인크. 생물학적 활성을 조절하기 위한 이특이성 결합제
US20060204505A1 (en) 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US20090061422A1 (en) 2005-04-19 2009-03-05 Linke Steven P Diagnostic markers of breast cancer treatment and progression and methods of use thereof
WO2007015935A2 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
WO2007041502A2 (en) 2005-09-30 2007-04-12 Monogram Biosciences Methods for determining responsiveness to cancer therapy
AU2005337051A1 (en) 2005-10-05 2007-04-12 Astrazeneca Uk Limited Method to predict or monitor the response of a patient to an ErbB receptor drug
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7897723B2 (en) 2006-04-07 2011-03-01 Københavns Universitet ErbB receptor-derived peptide fragments
CA2650776A1 (en) 2006-05-05 2007-11-15 Yale University Immunohistochemical methods for determining signal transduction activity in tumors
WO2008008500A2 (en) 2006-07-13 2008-01-17 Yale University Methods for making cancer prognoses based on the subcellular localization of biomarkers
JPWO2008032876A1 (ja) * 2006-09-15 2010-01-28 学校法人東海大学 Ｅｒ陰性およびｈｅｒ２陰性である乳癌の予防または治療剤およびそのスクリーニング方法
EP2094870A4 (en) 2006-11-03 2010-05-05 Univ Texas BIFUNCTIONAL PREDICTORS OF SENSITIVITY AND RESISTANCE TO CANCER THERAPY
CA2670522C (en) 2006-11-28 2018-08-07 U3 Pharma Gmbh Activated her3 as a marker for predicting therapeutic efficacy
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
EP2647388A1 (en) 2007-02-16 2013-10-09 Merrimack Pharmaceuticals, Inc. Antibodies Against ERBB3 and Uses Thereof
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
WO2008127710A2 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute Methods for treating cancer resistant to erbb therapeutics
JP2010526797A (ja) 2007-05-11 2010-08-05 エンゾン ファーマシューティカルズ，インコーポレーテッド Ｈｅｒ３のモジュレーションのためのｒｎａアンタゴニスト化合物
US20090054051A1 (en) 2007-08-22 2009-02-26 James Cavallo Attachable Headset for Portable Device
PL2288715T3 (pl) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
KR20110112301A (ko) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
IN2012DN01518A (enExample) 2009-08-21 2015-06-05 Merrimack Pharmaceuticals Inc
AU2010306774A1 (en) 2009-10-14 2012-05-03 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
US8895001B2 (en) 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
US8877687B2 (en) 2010-04-26 2014-11-04 Merrimack Pharmaceuticals Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
CA2803900A1 (en) 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
FR2963868B1 (fr) 2010-08-11 2012-09-28 Valeo Systemes Thermiques Echangeur de chaleur comprenant un element chauffant serigraphie
CA2819554A1 (en) 2010-12-10 2012-06-14 Merrimack Pharmaceuticals, Inc. Dosage and administration of bispecific scfv conjugates
US20140056898A1 (en) 2011-02-24 2014-02-27 Bo Zhang Combination therapies comprising anti-erbb3 agents
MX2013010379A (es) * 2011-03-11 2014-03-27 Merrimack Pharmaceuticals Inc Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas.
EA201301025A1 (ru) 2011-03-15 2014-01-30 Мерримак Фармасьютикалс, Инк. Преодоление устойчивости к ингибиторам пути erbb
CN103703026B (zh) 2011-04-19 2015-08-26 梅里麦克制药股份有限公司 单特异性和双特异性抗igf-1r和抗erbb3抗体
EP2704746A2 (en) 2011-05-06 2014-03-12 Merrimack Pharmaceuticals, Inc. Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents
WO2012177440A1 (en) 2011-06-24 2012-12-27 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-erbb3 antibodies in combination with paclitaxel
PH12013502663A1 (en) 2011-06-30 2018-03-21 Merrimack Pharmaceuticals Inc Dosage administration of anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers
WO2013023043A2 (en) * 2011-08-10 2013-02-14 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy
EP2833915A1 (en) 2012-04-02 2015-02-11 Merrimack Pharmaceuticals, Inc. Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3107578A2 (en) 2014-02-20 2016-12-28 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019952A2 (en) * 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5013004566; ＳＣＨＯＥＢＥＲＬ　ＢＩＲＧＩＴ: 'ＡＮ　ＥＲＢＢ３　ＡＮＴＩＢＯＤＹ　ＭＭ-１２１，ＩＳ　ＡＣＴＩＶＥ　ＩＮ　ＣＡＮＣＥＲＳ　ＷＩＴＨ　ＬＩＧＡＮＤ-ＤＥＰＥＮＤＥＮＴ　ＡＣＴＩＶＡＴＩＯＮ' ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖ７０　Ｎ６, 20100309, Ｐ２４８５-２４９４ *
JPN5013004567; ＨＡＲＲＩＳ　ＬＹＮＤＳＡＹ　Ｎ: 'ＭＯＬＥＣＵＬＡＲ　ＳＵＢＴＹＰＥＳ　ＯＦ　ＢＲＥＡＳＴ　ＣＡＮＣＥＲ　ＩＮ　ＲＥＬＡＴＩＯＮ　ＴＯ　ＰＡＣＬＩＴＡＸＥＬ　ＲＥＳＰＯＮＳＥ　ＡＮＤ　ＯＵＴＣＯＭＥＳ　以下備考' ＢＲＥＡＳＴ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖ８　Ｎ６, 20061127, Ｐ　Ｒ６６, ＣＵＲＲＥＮＴ　ＳＣＩＥＮＣＥ *
JPN5013004568; ＳＣＨＮＥＩＤＥＲ　Ｂ　Ｐ: 'ＴＲＩＰＬＥ-ＮＥＧＡＴＩＶＥ　ＢＲＥＡＳＴ　ＣＡＮＣＥＲ：　ＲＩＳＫ　ＦＡＣＴＯＲＳ　ＴＯ　ＰＯＴＥＮＴＩＡＬ　ＴＡＲＧＥＴＳ' ＣＬＩＮＩＣＡＬ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖ１４　Ｎ２４, 20081215, Ｐ８０１０-８０１８, ＴＨＥ　ＡＭＥＲＩＣＡＮ　ＡＳＳＯＣＩＡＴＩＯＮ　ＦＯＲ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ *
JPN6015008611; Ｃａｎｃｅｒ　Ｉｎｖｅｓｔｉｇａｔｉｏｎ Ｖｏｌ．　２７，Ｎｏ．　６, 2009, Ｐａｇｅｓ　６１３-６２３ *

Also Published As

Publication number Publication date
CN102858335A (zh) 2013-01-02
MX344355B (es) 2016-12-14
IL221693A (en) 2015-10-29
US20170291957A1 (en) 2017-10-12
WO2011112953A2 (en) 2011-09-15
UA111149C2 (uk) 2016-04-11
EP2859893A1 (en) 2015-04-15
US20190119401A1 (en) 2019-04-25
NZ602084A (en) 2014-07-25
US20130034548A1 (en) 2013-02-07
PT2544680E (pt) 2015-05-06
JP2016166203A (ja) 2016-09-15
EP2544680B1 (en) 2015-01-14
AU2011224186A1 (en) 2012-09-13
US20150132292A1 (en) 2015-05-14
MX2012010226A (es) 2013-01-29
SG183532A1 (en) 2012-09-27
CN102858335B (zh) 2015-04-15
PL2544680T3 (pl) 2015-08-31
KR20130005280A (ko) 2013-01-15
AU2011224186C1 (en) 2015-04-02
EP2544680A2 (en) 2013-01-16
AU2011224186B2 (en) 2014-10-23
HK1174254A1 (en) 2013-06-07
ES2535503T3 (es) 2015-05-12
WO2011112953A3 (en) 2011-12-01
CA2792327C (en) 2019-09-24
US8895001B2 (en) 2014-11-25
CA2792327A1 (en) 2011-09-15
US9518130B2 (en) 2016-12-13
EA201201186A1 (ru) 2013-11-29
JP6185102B2 (ja) 2017-08-23
KR101798679B1 (ko) 2017-11-16
BR112012022802A2 (pt) 2018-05-15
DK2544680T3 (en) 2015-04-27
ZA201206425B (en) 2015-08-26

Similar Documents

Publication Publication Date Title
JP6185102B2 (ja) トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用
AU2012229147B2 (en) Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
EP2815765A1 (en) Overcoming resistance to ERBB pathway inhibitors
AU2016207431B2 (en) Combination drug
CN110036030A (zh) 癌症的组合疗法
US20240218066A1 (en) Use of anti-pd-1 antibody in combination with first-line chemotherapy in treatment of advanced non-small cell lung cancer
HK1174254B (en) Use of erbb3 inhibitors in the treatment of triple negative breast cancer
NZ614427B2 (en) Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150304

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150828

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151109